These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10668404)

  • 1. Melatonin receptors and ligands.
    Witt-Enderby PA; Li PK
    Vitam Horm; 2000; 58():321-54. PubMed ID: 10668404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Melatonin, a pertinent prototype for therapeutic innovation].
    Lesieur D; Leclerc V; Chavatte P; Marot C; Renard P; Guardiola-Lemaitre B
    Therapie; 1998; 53(5):429-37. PubMed ID: 9921034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melatonin.
    Mor M; Plazzi PV; Spadoni G; Tarzia G
    Curr Med Chem; 1999 Jun; 6(6):501-18. PubMed ID: 10213796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.
    Rivara S; Mor M; Silva C; Zuliani V; Vacondio F; Spadoni G; Bedini A; Tarzia G; Lucini V; Pannacci M; Fraschini F; Plazzi PV
    J Med Chem; 2003 Apr; 46(8):1429-39. PubMed ID: 12672242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melatonin receptor pharmacology: toward subtype specificity.
    Sugden D; Pickering H; Teh MT; Garratt PJ
    Biol Cell; 1997 Nov; 89(8):531-7. PubMed ID: 9618903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-affinity relationships of indole-based melatonin analogs.
    Spadoni G; Mor M; Tarzia G
    Biol Signals Recept; 1999; 8(1-2):15-23. PubMed ID: 10085458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indole melatonin agonists and antagonists derived by shifting the melatonin side chain from the C-3 to the N-1 or to the C-2 indole position.
    Tarzia G; Diamantini G; Spadoni G
    Biol Signals Recept; 1999; 8(1-2):24-31. PubMed ID: 10085459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pharmacology and function of melatonin receptor subtypes.
    Dubocovich ML; Masana MI; Benloucif S
    Adv Exp Med Biol; 1999; 460():181-90. PubMed ID: 10810513
    [No Abstract]   [Full Text] [Related]  

  • 9. How does the melatonin receptor decode a photoperiodic signal in the pars tuberalis?
    Morgan PJ; Messager S; Webster C; Barrett P; Ross A
    Adv Exp Med Biol; 1999; 460():165-74. PubMed ID: 10810511
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecular pharmacology, regulation and function of mammalian melatonin receptors.
    Dubocovich ML; Rivera-Bermudez MA; Gerdin MJ; Masana MI
    Front Biosci; 2003 Sep; 8():d1093-108. PubMed ID: 12957828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of melatonin receptors agonists and antagonists.
    Tarzia G; Diamantini G; Mor M; Spadoni G
    Farmaco; 2000 Mar; 55(3):184-7. PubMed ID: 10919077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melatonin receptor ligands: A pharmaco-chemical perspective.
    Boutin JA; Witt-Enderby PA; Sotriffer C; Zlotos DP
    J Pineal Res; 2020 Oct; 69(3):e12672. PubMed ID: 32531076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The roles of valine 208 and histidine 211 in ligand binding and receptor function of the ovine Mel1a beta melatonin receptor.
    Conway S; Canning SJ; Barrett P; Guardiola-Lemaitre B; Delagrange P; Morgan PJ
    Biochem Biophys Res Commun; 1997 Oct; 239(2):418-23. PubMed ID: 9344844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study.
    Mor M; Rivara S; Silva C; Bordi F; Plazzi PV; Spadoni G; Diamantini G; Balsamini C; Tarzia G; Fraschini F; Lucini V; Nonno R; Stankov BM
    J Med Chem; 1998 Sep; 41(20):3831-44. PubMed ID: 9748358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rhodopsin-based model for melatonin recognition at its G protein-coupled receptor.
    Navajas C; Kokkola T; Poso A; Honka N; Gynther J; Laitinen JT
    Eur J Pharmacol; 1996 May; 304(1-3):173-83. PubMed ID: 8813600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melatonin: receptor-mediated events that may affect breast and other steroid hormone-dependent cancers.
    Baldwin WS; Barrett JC
    Mol Carcinog; 1998 Mar; 21(3):149-55. PubMed ID: 9537645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms.
    Dubocovich ML; Yun K; Al-Ghoul WM; Benloucif S; Masana MI
    FASEB J; 1998 Sep; 12(12):1211-20. PubMed ID: 9737724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research progress in the oncostatic mechanism of melatonin].
    Gao L; Xu RK
    Sheng Li Ke Xue Jin Zhan; 2001 Apr; 32(2):160-2. PubMed ID: 12545891
    [No Abstract]   [Full Text] [Related]  

  • 19. Melatonin and cardiovascular function.
    Krause DN; Geary GG; Doolen S; Duckles SP
    Adv Exp Med Biol; 1999; 460():299-310. PubMed ID: 10810525
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the structure-activity relationships of melatonin receptor agonists and antagonists: lengthening the N-acyl side-chain has differing effects on potency on Xenopus melanophores.
    Teh MT; Sugden D
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Nov; 358(5):522-8. PubMed ID: 9840420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.